Allergan plc. said Friday it has settled patent litigation with Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd, regarding its Delzicol (mesalamine) product, a treatment for ulcerative colitis. If the Food and Drugs Administration approves it, Zydus and Cadila may be able to sell their generic version of Delzicol from March 1, 2020, or earlier under certain circumstances, Allergan said in a statement. In the third quarter, Allergan said revenue from Delzicol and Asacol, another ulcerative colitis treatment, came to $72.2 million. Allergan shares were down 0.9% premarket, and are down 30% in the year so far, while the S&P 500 has gained 7.2%.
Copyright © 2016 MarketWatch, Inc.